Extension of SoluMatrix TM Abiraterone Acetate in Patients Who Completed Study Number CHL-AA-201

ClinicalTrials.gov ID: NCT02887976

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02887976. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 10:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open-label Extension (OLE), Expanded Access Study, to Assess Long-term Safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) With Methylprednisolone (4mg Bid) in Patients Who Completed Study Number CHL-AA-201

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

An Open-label extension (OLE), expanded access study, to assess long-term safety of SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) with Methylprednisolone (4mg bid) in patients who completed study number CHL-AA-201.

Study identification

NCT ID: NCT02887976
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: GU Research Network, LLC; Other
Enrollment: 2 participants

Conditions and interventions

Conditions

Prostate Cancer

Interventions

SoluMatrix™ Abiraterone Acetate Drug
Methylprednisolone Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: Male
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2016 (Type not available)
Primary completion: Oct 6, 2017 (Actual)
Completion: Oct 6, 2017 (Actual)
Last update posted: Jul 22, 2020

2016 – 2017

United States locations

U.S. sites: 3
U.S. states: 2
U.S. cities: 3

Facility	City	State	ZIP	Site status
GU Research Network/Wichita Urology Group	Wichita	Kansas	67226	—
GU Research Network/Urology PC	Lincoln	Nebraska	68516	—
GU Research Network/Urology Cancer Center	Omaha	Nebraska	68130	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02887976, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 22, 2020 · Synced Nov 13, 2026